Overview


According to FutureWise analysis the market for prenatal and new-born genetic testing in 2023 is US$ 6.1 billion, and is expected to reach US$ 14.81 billion by 2031 at a CAGR of 11.7%.

The development of many strategies to aid in the diagnosis of genetic abnormality in infants has been aided by technological developments in prenatal and new-born genetic testing. The fast advancement of prenatal genetic testing and foetal screening technology has opened up a plethora of diagnostic tools for the early diagnosis of genetic disorders and chromosomal abnormalities. The use of these technologically advanced goods has fueled research into factors that cause intellectual disability, rare genetic and genomic diseases, and birth deformities, among other things. The demand for prenatal genetic testing and screening will be fueled by technological advancements that improve the precision, efficacy, and feasibility of genetic tests. Prenatal genetic testing is a term used to describe tests done during pregnancy to see if the foetus has a genetic issue or a birth defect. It is done to see if there are any genetic diseases present, such as Tay-Sachs disease, cystic fibrosis, sickle cell anaemia, and Down's syndrome. After a baby is born, newborn genetic testing is performed to look for genetically inherited disorders or congenital anomalies such phenylketonuria, muscular spinal atrophy, serious congenital heart disease, hearing loss, and other conditions. Prenatal and newborn genetic tests are important in determining various possibilities during pregnancy in order to improve the baby's health prognosis. Prenatal and neonatal screening lowers infant mortality rates and improves patient outcomes. In addition, due to its superior safety and accuracy to invasive diagnostic procedures, the usage of noninvasive prenatal testing has grown over time. Several ethical concerns about prenatal and newborn testing, however, may stymie commercial growth. Infant mortality is linked to chromosomal abnormalities, which are one of the primary causes of death in children. Many countries are supporting the use of prenatal and newborn genetic testing as a result of the increased number of incidences of genetic abnormalities in infants. As a result, this aspect is driving the market's growth even more.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Prenatal and New-born Genetic Testing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Prenatal and New-born Genetic Testing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Ariosa Diagnostics
  • Berry Genomics Co. Ltd
  • BGI
  • Bio-Rad Laboratories, Inc
  • Illumina, Inc
  • Laboratory Corporation of America
  • Natera, Inc
  • Qiagen
  • Sequenom, Inc
  • Trivitron Healthcare
  • Verinata Health
  • Abbott
  • Agilent
  • AutoGenomics
  • Baebies
  • Biocartis Group NV
  • Masimo Corporation
  • PerkinElmer, Inc
  • Progenity, Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Technology

  • Screening
    • Non-invasive (NIPT)
    • Chorionic Villus Sampling (CVS)
    • Amniocentesis
    • Maternal Serum Screening (MSS)
    • Others
  • Diagnostic
    • mmPCR
    • Spectrophotometer
    • FISH
    • ASSAYS
    • Others

By Disease

  • Down’s Syndrome
  • Phenylketonuria
  • Cystic Fibrosis
  • Sickle Cell Anaemia
  • Others

By End-Use

  • Hospital
  • Maternity and Specialty Clinics
  • Diagnostic Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Prenatal and New-born Genetic Testing Market By Technology, By Disease, By End-Use and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Prenatal and New-born Genetic Testing Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Prenatal and New-born Genetic Testing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Prenatal and New-born Genetic Testing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Prenatal and New-born Genetic Testing Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Screening
         1.1. Non-invasive (NIPT)
         1.2. Chorionic Villus Sampling (CVS)
         1.3. Amniocentesis
         1.4. Maternal Serum Screening (MSS)
         1.5. Others
        2. Diagnostic
         2.1. mmPCR
         2.2. Spectrophotometer
         2.3. FISH
         2.4. ASSAYS
         2.5. Others

  • 8.   Prenatal and New-born Genetic Testing Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Down’s Syndrome
        2. Phenylketonuria
        3. Cystic Fibrosis
        4. Sickle Cell Anaemia
        5. Others

  • 9.   Prenatal and New-born Genetic Testing Market, By End-Use Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital
        2. Maternity and Specialty Clinics
        3. Diagnostic Centers

  • 10.   North America Prenatal and New-born Genetic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Prenatal and New-born Genetic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Prenatal and New-born Genetic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Prenatal and New-born Genetic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Ariosa Diagnostics
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Berry Genomics Co. Ltd
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BGI
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bio-Rad Laboratories, Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Illumina, Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Laboratory Corporation of America
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Natera, Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Qiagen
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sequenom, Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Trivitron Healthcare
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Verinata Health
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Abbott
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Agilent
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. AutoGenomics
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Baebies
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Biocartis Group NV
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Masimo Corporation
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. PerkinElmer, Inc
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Progenity, Inc
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients